Protagonist Therapeutics, Inc. $PTGX Shares Acquired by TD Asset Management Inc

TD Asset Management Inc increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 5.5% in the fourth quarter, Holdings Channel reports. The firm owned 158,730 shares of the company’s stock after buying an additional 8,302 shares during the period. TD Asset Management Inc’s holdings in Protagonist Therapeutics were worth $13,863,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $62,000. Osaic Holdings Inc. increased its position in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after purchasing an additional 525 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its position in shares of Protagonist Therapeutics by 222.4% during the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after purchasing an additional 656 shares during the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on PTGX. Citigroup reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Citizens Jmp raised their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Johnson Rice reissued a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Wedbush lifted their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $110.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $115.21.

Insider Activity

In related news, Director Harold E. Selick sold 24,000 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the sale, the director owned 60,845 shares in the company, valued at $6,388,725. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bryan Giraudo sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the sale, the director owned 31,825 shares of the company’s stock, valued at approximately $3,182,500. The trade was a 15.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 263,345 shares of company stock valued at $26,707,266 over the last 90 days. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Up 0.7%

PTGX stock opened at $98.03 on Tuesday. The business has a 50 day moving average price of $101.25 and a 200 day moving average price of $92.64. The stock has a market cap of $6.30 billion, a price-to-earnings ratio of -54.16 and a beta of 1.86. Protagonist Therapeutics, Inc. has a fifty-two week low of $49.38 and a fifty-two week high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.55. The firm had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.